论文部分内容阅读
目的分析不同剂量瑞舒伐他汀钙治疗老年冠心病合并高脂血症的临床疗效及安全性。方法将老年冠心病合并高脂血症患者60例随机分为A、B、C 3组,各20例。A组给予瑞舒伐他汀钙5mg口服,B组给予瑞舒伐他汀钙10mg口服,C组给予瑞舒伐他汀钙20mg口服,每天1次,晚餐后服用。治疗后对比3组患者的血脂水平及不良反应。结果 3组患者治疗后血清总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)水平均下降(P均<0.05),高密度脂蛋白胆固醇(HDL-C)水平升高(P均<0.05),且C组改善幅度优于A组、B组(P<0.05)。3组不良反应发生率比较差异无统计学意义(P>0.05)。结论剂量较大的瑞舒伐他汀钙更能有效控制老年冠心病患者的血脂水平,具有疗效好、安全性高的优点,值得推广。
Objective To analyze the clinical efficacy and safety of different doses of rosuvastatin calcium in the treatment of senile coronary heart disease complicated with hyperlipidemia. Methods Sixty elderly patients with coronary heart disease complicated with hyperlipidemia were randomly divided into A, B and C groups, 20 cases each. Group A received rosuvastatin calcium 5 mg orally, Group B received rosuvastatin calcium 10 mg orally, Group C received rosuvastatin calcium 20 mg orally, once daily and after dinner. After treatment, the blood lipid level and adverse reactions of three groups were compared. Results After treatment, the levels of total cholesterol (TC), triglyceride (TG) and low density lipoprotein cholesterol (LDL-C) decreased in all three groups (all P0.05) and HDL-C (P <0.05), and the improvement in group C was better than that in group A and group B (P <0.05). The incidence of adverse reactions in the three groups showed no significant difference (P> 0.05). Conclusion The higher dose of rosuvastatin calcium is more effective in controlling elderly patients with coronary heart disease lipid levels, with good efficacy, high safety advantages, it is worth promoting.